|
M.B. Antsiferov
CLINICAL INERTIA IN THE THERAPY OF TYPE 2 DIABETES MELLITUS
|
5-11 |
|
T.Yu.Demidova
SGLT 2INHIBITORS: PHARMACOLOGICAL GLYCOSURIA AS A NEW APPROACH TO THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS
|
12-18 |
|
A.M. Mkrtumyan
ALOGLIPTIN – EFFECTIVE AND SAFE DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN THE THERAPY OF TYPE 2 DIABETES MELLITUS
|
20-27 |
|
N.I.Volkova, M.I. Porksheyan
PERSONALIZED APPROACH TO THE REGIMEN OF INSULINOTHERAPY - IS THERE A PLACE FOR FEAR OF HYPOGLYCEMIA?
|
28-31 |
|
N.A. Chernikova, L.P. Ivanova, F.T. Abaeva
ADVANTAGES OF TIMELY INITIATION OF INSULIN THERAPY. RESULTS OF THE RUSSIAN OBSERVATIONAL PROGRAM HUBIN
|
32-37 |
|
A.F. Verbovoy, E.V. Mitroshina, Sharonova L.A.
ADIPOKINES AND CARDIOVASCULAR DISEASES
|
38-43 |
|
A.S. Ametov
ADVANTAGES OF FIXED COMBINATION OF SAXAGLIPTIN AND METFORMIN WITH MODIFIED RELEASE (KOMBOGLYCE PROLONG) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
|
44-52 |
|
M.B. Antsiferov (1), V.S.Pronin (2)
THE USE OF CLINICAL AND LABORATORY PREDICTORS FOR PROGNOSTICATION OF ANTISECRETORY AND ANTIPROLIFERATIVE EFFECTS OF SOMATOSTATIN ANALOGUES DURING THE TREATMENT OF ACROMEGALY: REVIEW OF RECENT RESEARCH
|
53-60 |
|
M.B. Antsiferov, O.M. Koteshkova
EFFICIENCY OF TRIPLE THERAPY USING LIRAGLUTIDE (VICTOZA) - FIRST LONG-ACTING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST - IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND VISCERAL OBESITY
|
61-66 |
|
O.L. Badalyan, A.A. Savenkov
POLYNEUROPATHY: CLINICAL MANIFESTATIONS, CLASSIFICATION, THERAPY
|
67-71 |
OSTEOPOROSIS |
|
I.Yu. Golovach
SKLEROSTIN AND ITS INHIBITORS - A NEW CONCEPT IN THE TREATMENT OF BONE DISORDERS: CERTAIN PAST, PROMISING FUTURE
|
72-77 |
|
A.Yu. Kochish, S.N. Ivanov, E.V. Sannikova
ADHERENCE TO THE DIAGNOSIS OF OSTEOPOROSIS IN PATIENTS WITH LOW-ENERGY FRACTURES
|
78-82 |
|
A.Yu. Kochish, S.N. Ivanov
CASE OF OSTEONECROSIS OF THE MAXILLA IN PATIENT WITH POSTMENOPAUSAL OSTEOPOROSIS AGAINST THE BACKGROUND OF PROLONGED TREATMENT WITH ANTIRESORPTIVE DRUGS
|
83-87 |
|
G.Sh.Golubev (1), V.A. Grebenschikov (2)
EFFECT OF THERAPY WITH STRONTIUM RANELATE ON THE TREATMENT OUTCOME IN PATIENTS WITH LOW-ENERGY FRACTURES OF THE ANKLE
|
88-95 |
Русский
